Download PDF
Klin Padiatr 2007; 219(6): 348-354
DOI: 10.1055/s-2007-971047
Originalarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Wegener-Granulomatose bei pädiatrischen Patienten

Wegener's Granulomatosis in Pediatric PatientsB. Fiebig 1 , C. M. Hedrich 1 , G. Heubner 2 , M. Gahr 1
  • 1Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden
  • 2Kinderklinik Freital, Weißeritztal-Kliniken, Freital
Further Information

Publication History

Publication Date:
30 November 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Wegener-Granulomatose (WG) ist eine im Kindes- und Jugendalter selten auftretende Erkrankung. Sie gehört neben dem Churg-Strauss-Syndrom und der mikroskopischen Polyangiitis zu den ANCA assoziierten Vaskuli-tiden. Vornehmlich betrifft die WG den oberen sowie unteren Atemwegstrakt und die Nieren. Die Krankheit ist gekennzeichnet durch einen chronischen Verlauf mit hoher Rezidivneigung. Bei persistierenden Beschwerden im Bereich des Respirationstraktes, welche sich nicht als Infektion oder Allergie bestätigen, ist differenzialdiagnostisch auch an eine WG zu denken.Trotz gebesserter Prognose seit Einführung der immunsuppressiven Therapie bleibt die WG eine sehr ernst zu nehmende Erkrankung, welche in ca. einem Drittel der Fälle zu chronischer Niereninsuffizienz bis zum terminalen Nierenversagen führen kann. Frühe Kombinationsbehandlung mit dem Ziel der Remission und Verbesserung der Prognose ist dringend indiziert. Zur Erhaltungstherapie sollten aufgrund der Langfristigkeit der Behandlung weniger toxische Immunsuppressiva (z. B. Methotrexat) verwendet werden.

Abstract

Wegener's Granulomatosis (WG) is a disease occurring rarely in childhood and adolescence. Together with the Churg-Strauss-Syndrome and the microscopic Polyangiitis it belongs to the vasculitis syndromes associated with ANCA. WG mostly affects the upper and lower respiratory tract and kidneys. It is characterized by a chronic development and high tendency to relapse. In cases of persistent disturbances of the respiratory system which do not have infectious or allergic geneses differential diagnosis should also consider WG.Although clinical course and prognosis have improved since the introduction of immunosuppressive therapy, WG, leading to renal failure in about one third of all cases, remains a disease which has to be taken seriously. Early treatment has been proven to improve prognosis. Due to the necessity of longterm treatment less toxic immunosuppressive therapy should be applied (e.g. Methotrexate).

Schlüsselwörter

Wegener-Granulomatose - Vaskulitis - Vaskulitiden Therapie - Kindesalter

Key words

Wegener's granulomatosis - vasculitis - vasculitis treatment - childhood

Literatur

  • 1 Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis.  Pediatr Nephrol. 2002;  17 754-761
    CrossrefPubMedGoogle Scholar
  • 2 Boomsma MM. et al . Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmatic antibody levels: a prospective study.  Arthritis Rheum. 2000;  43 2025-2033
    PubMedGoogle Scholar
  • 3 Booth A, Harper L, Hammad T, Bacon P. et al . Prospektive study of TNFα blockade with Infliximab in antineutrophil cytoplasmatic antibody-associated systemic vasculitis.  J Am Soc Nephrol. 2004;  15 717-721
    CrossrefPubMedGoogle Scholar
  • 4 Cohen Tervaert JW, Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, Meijer S, Giessen M van der, Hem GK van der. The Association between active Wegener's granulomatosis and anticytoplasmic antibodies.  Arch Intern Med. 1989;  149 2461-2465
    CrossrefPubMedGoogle Scholar
  • 5 De Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nölle B, Gross WL. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulphamethoxazole.  Arthritis Rheum. 1996;  39 2052-2061
    PubMedGoogle Scholar
  • 6 Dijstelbloem HM, Scheepers RH, Oost WW. et al . Fc gamma receptor polymorphisms in Wegener's granulomatosis: risk faktor for disease relapse.  Arthritis Rheum. 1999;  42 1823-1827
    CrossrefPubMedGoogle Scholar
  • 7 Elkon KB, Sutherland DC, Rees AJ, Hughes GR, Batchelor JR. HLA antigen frequencies in systemic vasculitis: increase in HLA-DR2 in Wegener's granulomatosis.  Arthritis Rheum. 1983;  26 102-105
    PubMedGoogle Scholar
  • 8 Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis.  N Engl J Med. 1979;  301 235-238
    CrossrefPubMedGoogle Scholar
  • 9 Frosch M, Foell D. Wegener granulomatosis in childhood and adolescence.  Eur J Pediatr. 2004;  163 425-434
    PubMedGoogle Scholar
  • 10 Guillevan L, Cordier JF, Lhote F, Cohen P. et al . A prospective, multicenter, randomised trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.  Arthritis Rheum. 1997;  40 2187-2198
    CrossrefPubMedGoogle Scholar
  • 11 Gordon M, Luqmani RA, Adu D. et al . Relapses in patients with a systemic vasculitis.  Q J Med. 1993;  86 779-789
    PubMedGoogle Scholar
  • 12 Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmatic antibody-associated vasculitis and renal invovement. A prospective, randomised study.  Arthritis Rheum. 1998;  41 1835-1844
    CrossrefPubMedGoogle Scholar
  • 13 Hoffman GS. Immunosuppressive therapy is always required for the treatment of limited Wegener's granulomatosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1996;  13 249-252
    PubMedGoogle Scholar
  • 14 Hoffman GS. Wegener's granulomatosis: the path traveled since 1931.  Medicin (Baltimore). 1994;  73 325-329
    PubMedGoogle Scholar
  • 15 Hoffman GS, Kerr GS, Leavitt RY. et al . Wegener granulomatosis: an analysis of 158 patients.  Ann Intern Med. 1992;  116 488-498
    CrossrefPubMedGoogle Scholar
  • 16 Hoffman GS, Leavitt RY, Kerr GS. et al . Treatment of Wegener's Granulomatosis with glucocorticoids and Methotrexate.  Arthritis Rheum. 1992;  35 1322-1329
    PubMedGoogle Scholar
  • 17 Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis.  Ann Intern Med. 1967;  67 393-398
    PubMedGoogle Scholar
  • 18 Joy SM, Hogan LS, Jennete C, Falk JR, Nachman HP. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis.  Nephrol Dial Transplant. 2005;  20 2725-2732
    CrossrefPubMedGoogle Scholar
  • 19 Katz P, Alling DW, Haynes BF, Fauci AS. Association of Wegener's granulomatosis with HLA-B8.  Clin Immunol Immunpathol. 1979;  14 268-270
    CrossrefPubMedGoogle Scholar
  • 20 Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for Refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial.  AJRCCM. 2006;  173 180-187
    PubMedGoogle Scholar
  • 21 Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmatic antibody titer in patients with Wegener's granulomatosis.  Arthritis Rheum. 1993;  36 365-371
    PubMedGoogle Scholar
  • 22 Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis.  Rheumatology (Oxford). 2002;  41 572-581
    CrossrefPubMedGoogle Scholar
  • 23 Langford CA, Hoffman GS. Wegener's granulomatosis.  Thorax. 1999;  54 629-637
    CrossrefPubMedGoogle Scholar
  • 24 Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse.  Am J Med. 2003;  114 463-469
    CrossrefPubMedGoogle Scholar
  • 25 Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.  Arthritis Rheum. 1999;  42 2666-2673
    CrossrefPubMedGoogle Scholar
  • 26 Lindsley CD, Laxer RM. Granulomatous vasculitis, Giant cell arteriitis and sarcoidosis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Hrsg) Textbook of Pediatric Rheumatology. Elsevier Saunders, Philadelphia 2005: S 539-S 560
    Google Scholar
  • 27 Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, Woude FJ van der. Mycophenolate Mofetil for Maintenance Therapy of Wegener's Granulomatosis and Microscopic Polyangiitis: a pilot study in 11 patients with renal involvement.  J Am Soc Nephrol. 1999;  10 1965-1971
    PubMedGoogle Scholar
  • 28 Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.  Annals of Rheumatology Dis.. 2006;  65 936-941
    PubMedGoogle Scholar
  • 29 Papiha SS, Murty GE, Ad’Hia A, Mains BT, Venning M. Association of Wegener's granulomatosis with HLA antigens and other genetic markers.  Ann Rheum Dis. 1992;  51 246-248
    PubMedGoogle Scholar
  • 30 Raynold JP, Bloch DA, Fries JF. Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis.  J Rheumatol. 1993;  20 1524-1526
    PubMedGoogle Scholar
  • 31 Reinhold-Keller E, Fink C, Herlyn K, Gross WL, Groot K De. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate.  Arthritis and Rheumatism. 2002;  47 326-332
    CrossrefPubMedGoogle Scholar
  • 32 Rottem M, Fauci AS, Hallahan CW. et al . Wegener granulomatosis in children and adolescents: clinical presentation and outcome.  J Pediatr. 1993;  122 26-31
    CrossrefPubMedGoogle Scholar
  • 33 Ruder H, Rieger CHL. Wegener Granulomatose. In: Wahn V (Hrsg) Rheumatische Erkrankungen im Kindes- und Jugendalter. Hans Marseille Verlag, München 2001: 346-355
    Google Scholar
  • 34 Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic Accurance of Serological Assays in Pediatric Inflammatory Bowel Disease.  Gastroenterology. 1998;  115 822-829
    PubMedGoogle Scholar
  • 35 Sanders JS, Stassen PM, Rossum AP van, Kallenberg CG, Stegeman CA. Risk factors for relapse in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis: tools for treatment decisions?.  Clin Exp Rheumatol. 2004;  22 94-101
    PubMedGoogle Scholar
  • 36 Sarraf P, Sneller MC. Pathogenesis of Wegener's granulomatosis: current concepts.  Expert Rev Mol Med May 13. 2005;  7 1-19
    PubMedGoogle Scholar
  • 37 Segelmark M, Elzouki AN, Wieslander J, Eriksson S. The PiZ gene in alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis.  Kidney Int. 1995;  48 844-850
    CrossrefPubMedGoogle Scholar
  • 38 Slater CA, Liang MH, MacCune JW, Christman GM, Laufer MR. Preserving ovarian function in patients receiving cyclophosphamide.  Lupus. 1999;  8 3-10
    CrossrefPubMedGoogle Scholar
  • 39 Sneller MC, Fauci AS. Pathogenesis of vasculitis syndromes.  Med Clin North AM. 1997;  81 221-242
    PubMedGoogle Scholar
  • 40 Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener'sgranulomatosis patients treated with methotrexate and prednisone.  Arthritis Rheum. 1995;  38 608-613
    CrossrefPubMedGoogle Scholar
  • 41 Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmatic antibody-associated vasculitis treated with rituximab.  Rheumatology. 2006;  1-5 , [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 42 Stegeman CA, Travaert JW, Sluiter WJ. et al . Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis.  Ann Intern Med. 1994;  120 12-17
    PubMedGoogle Scholar
  • 43 Stegmayr BG, Gothefors L, Malmer B, Müller Wiefel DE, Nilsson K, Sundelin B. Wegener granulomatosis in children and young adults.  Pediatr Nephrol. 2000;  14 208-213
    CrossrefPubMedGoogle Scholar
  • 44 Stone JH, Uhlfelder ML, Hellmann DB. et al . Etanercept combined with conventional treatment in Wegener's granulomatosis: a six month open-label trial to evaluate safety.  Arthritis Rheum. 2001;  44 1149-1154
    CrossrefPubMedGoogle Scholar
  • 45 Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, MacCune WJ, Ytterberg SR, Allen NB, Hoffman GS. Solid Malignancies among Patients in the Wegener's Granulomatosis Etanercept Trial.  Arthritis and Rheumatism. 2006;  54 1608-1618
    CrossrefPubMedGoogle Scholar
  • 46 Geld YM van der, Limburg PC, Kallenberg CG. Proteinase 3, Wegener's autoantigen: from gene to antigen.  J Leukoc Biol. 2001;  69 177-190
    PubMedGoogle Scholar
  • 47 Walton EW. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis).  BMJ. 1958;  2 265-270
    CrossrefPubMedGoogle Scholar
  • 48 Wegener's Granulomatosis Etanercept Trial (WGET) Research Group . Etanercept plus standard therapy for Wegener's granulomatosis.  N Engl J Med. 2005;  352 351-361
    CrossrefPubMedGoogle Scholar
  • 49 Weiner SR, Paulus HE. Treatment of Wegener's granulomatosis.  Semin Respir Med. 1989;  10 156-161
    Article in Thieme ConnectPubMedGoogle Scholar

Korrespondenzadresse

B. Fiebig

Universitätsklinikum

Carl Gustav Carus

Klinik und Poliklinik für Kinderheilkunde

Fetscherstraße 74

01307 Dresden

Email: barbara.fiebig@uniklinikum-dresden.de

      >